TRVI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Trevi Therapeutics Inc (TRVI) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. While the technical indicators show some bullish signals, the lack of significant positive catalysts, weak financial performance, and neutral sentiment from hedge funds and insiders suggest that this stock does not currently present an optimal long-term investment opportunity.
The technical indicators show mixed signals. The MACD is positive and contracting, indicating some bullish momentum. The RSI is neutral at 46.188, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is trading close to its pivot level (11.095), with resistance at 11.735 and support at 10.455. This suggests limited upside potential in the short term.
Analyst Stifel recently raised the price target from $15 to $18 and maintained a Buy rating, which reflects some confidence in the stock's future performance.
No recent news or significant trading activity from hedge funds, insiders, or Congress. Additionally, the stock's financial performance is weak, with declining net income (-10.87% YoY) and EPS (-38.46% YoY).
In Q3 2025, Trevi Therapeutics reported no revenue growth (0% YoY) and a net income decline of -10.87% YoY to -$11.8 million. EPS also dropped significantly by -38.46% YoY to -0.08, indicating poor financial health.
Stifel raised the price target to $18 from $15 and maintained a Buy rating, reflecting optimism for the stock's long-term potential.
